Gastroenterology Journals

The list of the following gastroenterology journal links are provided below for you and your staff.

Gastroenterology & Endoscopy News
www.gastroendonews.com: An independent monthly newspaper designed to keep physicians current on the latest developments in gastroenterology and endoscopy.
Clinical Gastroenterology & Hepatology
www.cghjournal.org: The official clinical practice journal of the AGA institute. Free access to abstracts; full-text versions are limited to subscribers.
American Journal of Gastroenterology
www.amjgastro.com: Publication of the American College of Gastroenterology. Online version is fully accessible to ACG members only.
Practical Gastroenterology
www.practicalgastro.com: A professional clinical journal focusing on the diagnosis and management of digestive diseases.
Nature Clinical Practice Gastroenterology & Hepatology
www.gi.org/physicians/nature.asp: An official publication of the American College of Gastroenterology. Online version is fully accessible to ACG members only.
Journal of Gastroenterology & Hepatology
www.blackwellpublishing.com/jgh: Features papers, reviews, and editorials concerned with clinical practice and research in hepatology, gastroenterology and endoscopy. An online subscription or article purchase is necessary to view online articles.
Inflammatory Bowel Diseases Journal
www.ibdjournal.com: The official journal of the Crohn's and Colitis Foundation of America, Inc. Available online to CCFA professional members.

Important Safety Information

PENTASA is indicated for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis.

PENTASA is generally well tolerated. In worldwide clinical trials (N>2100), the most common adverse events were diarrhea (3.4%), headache (2.0%), nausea (1.8%), abdominal pain (1.7%), dyspepsia (1.6%), vomiting (1.5%), and rash (1.0%). As with other mesalamine products, serious adverse events may occur. PENTASA is contraindicated in patients with a hypersensitivity to salicylates. Caution should be used in patients with impaired hepatic or renal function. Patients with pre-existing renal disease, increased BUN or serum creatinine, or proteinuria should be monitored during PENTASA therapy.